A Phase I Trial of RO5126766 (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma

Trial Profile

A Phase I Trial of RO5126766 (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs RG 7304 (Primary)
  • Indications Multiple myeloma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results (n=20) of data from the RAS/RAF-mutated advanced solid tumor cohort and the initial results for the multiple myeloma (MM) cohort presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results of preliminary analysis (n=18) assessing the tolerability and activity in patients with KRAS, NRAS or BRAFmutated tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Interim results in 29 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top